🎉 M&A multiples are live!
Check it out!

Nautilus Biotechnology Valuation Multiples

Discover revenue and EBITDA valuation multiples for Nautilus Biotechnology and similar public comparables like Zomedica, AnteoTech, and Biohit.

Nautilus Biotechnology Overview

About Nautilus Biotechnology

Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.


Founded

2016

HQ

United States of America
Employees

155

Website

nautilus.bio

Financials

LTM Revenue n/a

LTM EBITDA -$73.5M

EV

-$0.8M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Nautilus Biotechnology Financials

Nautilus Biotechnology has a last 12-month revenue of n/a and a last 12-month EBITDA of -$73.5M.

In the most recent fiscal year, Nautilus Biotechnology achieved revenue of n/a and an EBITDA of -$75.1M.

Nautilus Biotechnology expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Nautilus Biotechnology valuation multiples based on analyst estimates

Nautilus Biotechnology P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$70.4M -$75.1M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$57.9M -$63.7M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Nautilus Biotechnology Stock Performance

As of April 15, 2025, Nautilus Biotechnology's stock price is $1.

Nautilus Biotechnology has current market cap of $98.7M, and EV of -$0.8M.

See Nautilus Biotechnology trading valuation data

Nautilus Biotechnology Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$0.8M $98.7M XXX XXX XXX XXX $-0.57

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Nautilus Biotechnology Valuation Multiples

As of April 15, 2025, Nautilus Biotechnology has market cap of $98.7M and EV of -$0.8M.

Nautilus Biotechnology's trades at n/a LTM EV/Revenue multiple, and 0.0x LTM EBITDA.

Analysts estimate Nautilus Biotechnology's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Nautilus Biotechnology and 10K+ public comps

Nautilus Biotechnology Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$0.8M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 0.0x XXX XXX XXX
P/E -1.4x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Nautilus Biotechnology Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Nautilus Biotechnology Valuation Multiples

Nautilus Biotechnology's NTM/LTM revenue growth is Infinity%

Nautilus Biotechnology's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.5M for the same period.

Over next 12 months, Nautilus Biotechnology's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Nautilus Biotechnology's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Nautilus Biotechnology and other 10K+ public comps

Nautilus Biotechnology Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 7% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Nautilus Biotechnology Public Comps

See public comps and valuation multiples for Pharma Diagnostics & Analytics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Zomedica XXX XXX XXX XXX XXX XXX
AnteoTech XXX XXX XXX XXX XXX XXX
Proteomics International XXX XXX XXX XXX XXX XXX
Biohit XXX XXX XXX XXX XXX XXX
Genomictree XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Nautilus Biotechnology M&A and Investment Activity

Nautilus Biotechnology acquired  XXX companies to date.

Last acquisition by Nautilus Biotechnology was  XXXXXXXX, XXXXX XXXXX XXXXXX . Nautilus Biotechnology acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Nautilus Biotechnology

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Nautilus Biotechnology

When was Nautilus Biotechnology founded? Nautilus Biotechnology was founded in 2016.
Where is Nautilus Biotechnology headquartered? Nautilus Biotechnology is headquartered in United States of America.
How many employees does Nautilus Biotechnology have? As of today, Nautilus Biotechnology has 155 employees.
Who is the CEO of Nautilus Biotechnology? Nautilus Biotechnology's CEO is Mr. Sujal M. Patel.
Is Nautilus Biotechnology publicy listed? Yes, Nautilus Biotechnology is a public company listed on NAS.
What is the stock symbol of Nautilus Biotechnology? Nautilus Biotechnology trades under NAUT ticker.
When did Nautilus Biotechnology go public? Nautilus Biotechnology went public in 2021.
Who are competitors of Nautilus Biotechnology? Similar companies to Nautilus Biotechnology include e.g. Zomedica, AnteoTech, Proteomics International, Biohit.
What is the current market cap of Nautilus Biotechnology? Nautilus Biotechnology's current market cap is $98.7M
What is the current EBITDA of Nautilus Biotechnology? Nautilus Biotechnology's last 12-month EBITDA is -$73.5M.
What is the current EV/EBITDA multiple of Nautilus Biotechnology? Current EBITDA multiple of Nautilus Biotechnology is 0.0x.
Is Nautilus Biotechnology profitable? Yes, Nautilus Biotechnology is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.